Detailed information for compound 1634952

Basic information

Technical information
  • Name: Unnamed compound
  • MW: 290.319 | Formula: C17H14N4O
  • H donors: 1 H acceptors: 2 LogP: 2.12 Rotable bonds: 2
    Rule of 5 violations (Lipinski): 1
  • SMILES: N#Cc1cccc(c1)C1(NC(=N)N(C1=O)C)c1ccccc1
  • InChi: 1S/C17H14N4O/c1-21-15(22)17(20-16(21)19,13-7-3-2-4-8-13)14-9-5-6-12(10-14)11-18/h2-10H,1H3,(H2,19,20)
  • InChiKey: OYLIDUDLEDFVAK-UHFFFAOYSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

No synonyms found for this compound

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Homo sapiens beta-site APP-cleaving enzyme 1 Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
Species Potential target Known druggable target/s Ortholog Group
Schistosoma mansoni memapsin-2 (A01 family) Get druggable targets OG5_135830 All targets in OG5_135830
Schistosoma japonicum ko:K07747 beta-site APP-cleaving enzyme 2 (memapsin 1) [EC3.4.23.45], putative Get druggable targets OG5_135830 All targets in OG5_135830
By sequence similarity to non orthologous known druggable targets
Species Potential target Known druggable target Length Alignment span Identity
Plasmodium falciparum plasmepsin VII beta-site APP-cleaving enzyme 1 401 aa 352 aa 21.3 %
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Plasmodium falciparum plasmepsin IV 0.0021 0 0.5
Toxoplasma gondii eukaryotic aspartyl protease superfamily protein 0.0021 0 0.5
Onchocerca volvulus 0.0021 0 0.5
Trichomonas vaginalis Clan AA, family A1, cathepsin D-like aspartic peptidase 0.0021 0 0.5
Plasmodium falciparum plasmepsin I 0.0021 0 0.5
Toxoplasma gondii aspartyl protease ASP3 0.0021 0 0.5
Echinococcus granulosus integrin linked protein kinase 0.0612 1 1
Plasmodium vivax plasmepsin IV, putative 0.0021 0 0.5
Toxoplasma gondii aspartyl protease 0.0021 0 0.5
Plasmodium vivax aspartyl protease, putative 0.0021 0 0.5
Plasmodium falciparum plasmepsin VI 0.0021 0 0.5
Plasmodium falciparum plasmepsin IX 0.0021 0 0.5
Plasmodium vivax aspartyl protease, putative 0.0021 0 0.5
Schistosoma mansoni protein kinase 0.0612 1 1
Plasmodium falciparum plasmepsin II 0.0021 0 0.5
Schistosoma mansoni memapsin-2 (A01 family) 0.0521 0.8456 0.8456
Plasmodium falciparum plasmepsin III 0.0021 0 0.5
Loa Loa (eye worm) TKL/MLK/ILK protein kinase 0.0612 1 1
Plasmodium vivax aspartyl proteinase, putative 0.0021 0 0.5
Plasmodium vivax aspartyl proteinase, putative 0.0021 0 0.5
Echinococcus multilocularis integrin linked protein kinase 0.0612 1 1
Plasmodium falciparum plasmepsin VIII, putative 0.0021 0 0.5
Onchocerca volvulus 0.0021 0 0.5
Toxoplasma gondii aspartyl proteinase (eimepsin), putative 0.0021 0 0.5
Schistosoma mansoni protein kinase 0.0612 1 1
Plasmodium falciparum plasmepsin V 0.0021 0 0.5
Plasmodium falciparum plasmepsin X 0.0021 0 0.5
Plasmodium vivax plasmepsin V, putative 0.0021 0 0.5
Toxoplasma gondii aspartyl protease ASP1 0.0021 0 0.5
Plasmodium vivax aspartyl protease, putative 0.0021 0 0.5
Plasmodium falciparum plasmepsin VII 0.0021 0 0.5

Activities

Activity type Activity value Assay description Source Reference
Ki (binding) = 0.37 uM Inhibition of human BACE1 using QSY7EISEVNLDAEFC-Eu-amide as substrate incubated for 30 mins prior to substrate addition measured after 90 mins by FRET analysis ChEMBL. 22390835

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.